In a phase 2b randomized trial involving adults with type 2 diabetes, cotadutide—another glucagon/GLP-1 receptor agonist—demonstrated significant improvements in glycemic control and body weight, compared to placebo (p < 0.001 for all measures). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.